Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 100mg/mL
tablets
- 25mg
- 50mg
- 100mg
- 200mg
- 250mg
- 500mg
tablets, sustained release
- 500mg
Isoniazid (INH) Overdose
1 g per gram INH ingested or 70 mg/kg IV if unknown, may require 1 g q30min; not to exceed 5 g with unclear history
Prevention of Drug-Induced Neuritis
10-50 mg/day PO (penicillamine or INH); 100-300 mg/day (cycloserine)
Ethylene Glycol Toxicity
100 mg IV q6hr for 2 days
Gyromitrin Poisoning
25 mg/kg IV infusion over 15-30 min; repeat PRN up to 15-20 g/day
Use in conjunction with benzodiazepines, phenobarbital
Other Indications & Uses
Toxicity due cycloserine OD, penicillamine OD, hydrazine ingestion, or Gyromitra mushrooms (contains monomethylhydrazine precursors)
May be effective in ginkgo biloba seed toxicity
Dosage Forms & Strengths
injectable solution
- 100mg/mL
tablets
- 25mg
- 50mg
- 100mg
- 200mg
- 250mg
- 500mg
tablets, sustained release
- 500mg
Isoniazid (INH) Overdose
1 g per gram INH ingested or 70 mg/kg IV if unknown, may require 1 g q30min, not to exceed 5 g with unclear history
Prevention of Drug-Induced Neuritis
1-2 mg/kg/24 hr PO
Ethylene Glycol Toxicity
1-2 mg/kg IV during first 24 hr
Gyromitrin Poisoning
25 mg/kg IV infusion over 15-30 min, repeat PRN up to 15-20 g/day
Use in conjunction with benzodiazepines, phenobarbital
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
Frequency Not Defined
Incoordination
Headache
Somnolence
Increased AST
Ataxia
Neuropathy
Paresthesia
Seizures
Death in large doses
Delayed peripheral neurotoxicity long term
Pregnancy & Lactation
Pregnancy Category: A
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Shunts metabolism of ethylene glycol to nontoxic nonoxalates
Helps replete GABA depleted by INH or monomethylhydrazine
Administration
INH seizure: slow IV rate 0.5 g/min; remaining dose infused over 4-6 hr since seizure ceases to maintain pyridoxine avail. as INH metabolizes
Gyromitra: infuse over 15-30 min
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
